WO2004039362A3 - Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies - Google Patents

Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies Download PDF

Info

Publication number
WO2004039362A3
WO2004039362A3 PCT/US2003/034157 US0334157W WO2004039362A3 WO 2004039362 A3 WO2004039362 A3 WO 2004039362A3 US 0334157 W US0334157 W US 0334157W WO 2004039362 A3 WO2004039362 A3 WO 2004039362A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
treatment
hypoestoxides
hyperlipidemia
agonists
Prior art date
Application number
PCT/US2003/034157
Other languages
English (en)
Other versions
WO2004039362A2 (fr
Inventor
Emeka J Nchekwube
Emmanuel A Ojo-Amaize
Howard B Cottam
Original Assignee
Paraquest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paraquest Inc filed Critical Paraquest Inc
Priority to AU2003286721A priority Critical patent/AU2003286721A1/en
Priority to BR0306632-0A priority patent/BR0306632A/pt
Priority to DE60305727T priority patent/DE60305727T2/de
Priority to CA002509834A priority patent/CA2509834A1/fr
Priority to EP03777932A priority patent/EP1558240B1/fr
Publication of WO2004039362A2 publication Critical patent/WO2004039362A2/fr
Publication of WO2004039362A3 publication Critical patent/WO2004039362A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement et de prophylaxie d'hyperlipidémies, notamment de l'hypertriglycéridémie et de l'hypercholestérolémie. Ces méthodes consistent à administrer à un hôte une quantité thérapeutiquement ou prophylactiquement efficace d'un composé de diterpène, tel qu'un hypoestoxyde.
PCT/US2003/034157 2002-10-28 2003-10-28 Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies WO2004039362A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003286721A AU2003286721A1 (en) 2002-10-28 2003-10-28 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia
BR0306632-0A BR0306632A (pt) 2002-10-28 2003-10-28 Hipoestóxidos, seus derivados e agonistas para uso no tratamento e profilaxia de hiperlipidemia
DE60305727T DE60305727T2 (de) 2002-10-28 2003-10-28 Hypoestoxide, derivate und agonisten davon zur verwendung bei der behandlung und prophylaxe von hyperlipidämie
CA002509834A CA2509834A1 (fr) 2002-10-28 2003-10-28 Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies
EP03777932A EP1558240B1 (fr) 2002-10-28 2003-10-28 Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42153302P 2002-10-28 2002-10-28
US60/421,533 2002-10-28

Publications (2)

Publication Number Publication Date
WO2004039362A2 WO2004039362A2 (fr) 2004-05-13
WO2004039362A3 true WO2004039362A3 (fr) 2004-07-08

Family

ID=32230237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034157 WO2004039362A2 (fr) 2002-10-28 2003-10-28 Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies

Country Status (9)

Country Link
US (1) US20040087553A1 (fr)
EP (1) EP1558240B1 (fr)
CN (1) CN1731992A (fr)
AT (1) ATE327749T1 (fr)
AU (1) AU2003286721A1 (fr)
BR (1) BR0306632A (fr)
CA (1) CA2509834A1 (fr)
DE (1) DE60305727T2 (fr)
WO (1) WO2004039362A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229979B2 (en) * 2003-06-23 2007-06-12 Immune Modulation, Inc. Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents
US20060094695A1 (en) * 2004-11-02 2006-05-04 Paraquest, Inc. Hypoestoxides, derivatives and agonists thereof for use in the prophylaxis and treatment of obesity
US10857122B2 (en) * 2015-03-09 2020-12-08 Immune Modulation, Inc. Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
WO2001001975A2 (fr) * 1999-07-06 2001-01-11 Paraquest, Inc. Hypoestoxydes, leurs derives et leurs agonistes utilises comme antiparasitaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5994328A (en) * 1998-01-14 1999-11-30 Immune Modulation, Inc. Hypoestoxides, derivatives and agonists thereof for use as anticancer agents
US6001871A (en) * 1998-01-15 1999-12-14 Immune Modulation, Inc. Hypoestoxides, derivatives and agonists thereof for use as antiviral agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
WO2001001975A2 (fr) * 1999-07-06 2001-01-11 Paraquest, Inc. Hypoestoxydes, leurs derives et leurs agonistes utilises comme antiparasitaires
US6242484B1 (en) * 1999-07-06 2001-06-05 Paraquest, Inc. Hypoestoxides, derivatives and agonists thereof for use of antiparasitic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. A. OJO-AMAIZE ET AL: "hypoestoxide, a Natural Nonmutagenic Diterpenoid with Antiangiogenic and Antitumor Activity: Possible Mechanisms of Action", CANCER RESEARCH, vol. 62, 15 July 2002 (2002-07-15), pages 4007 - 4014, XP002279020 *

Also Published As

Publication number Publication date
US20040087553A1 (en) 2004-05-06
EP1558240A2 (fr) 2005-08-03
DE60305727T2 (de) 2007-05-31
EP1558240B1 (fr) 2006-05-31
WO2004039362A2 (fr) 2004-05-13
DE60305727D1 (de) 2006-07-06
CN1731992A (zh) 2006-02-08
ATE327749T1 (de) 2006-06-15
BR0306632A (pt) 2004-09-28
AU2003286721A1 (en) 2004-05-25
CA2509834A1 (fr) 2004-05-13

Similar Documents

Publication Publication Date Title
AR019671A1 (es) Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento
AU2003258402A1 (en) The use of resveratrol to regulate expression of apolipoprotein a1
WO2004055006A8 (fr) Nouveaux composes presentant un effet inhibiteur selectif de la gsk3
WO2004041269A3 (fr) Nouvel emploi pour composition pharmaceutique
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2000276362A1 (en) Composition for the treatment of diabetes
WO2007130822A3 (fr) Modulateurs des récepteurs mglur5 iii
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
WO2004010936A3 (fr) Composes selectifs des recepteurs ppar alpha destines au traitement de la dyslipidemie et d'autres troubles lipidiques
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
AU2001294673A1 (en) Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
AU2003285281A1 (en) Topical application of curcumin for the treatment of peripheral neuropathy
WO2004039362A3 (fr) Hypoestoxydes, derives et agonistes de ces derniers a utiliser dans le traitement et la prophylaxie d'hyperlipidemies
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003264707A1 (en) Use of a chrysanthellum extract
EP0982031A3 (fr) Composition antifongique contenant voriconazole et trovafloxacine ou promedicaments de celles-ci
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU4920200A (en) Compositions for the preserving treatment of feeds
WO2001055108A3 (fr) Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003777932

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2509834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038A78605

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003777932

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003777932

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP